SOLENO THERAPEUTICS INC (SLNO): debt financing — Soleno initiates $100M accelerated share repurchase; amends loan facility

SOLENO THERAPEUTICS INC

Entered $100M accelerated share repurchase with Jefferies; initial delivery of ~1,511,553 shares.
Repurchase expected to complete in Q1 2026; final shares based on VWAP less discount.
Amended Oxford loan facility to permit ASR; $50M committed Term C/D loans removed; remaining $100M uncommitted.
CEO cites Q3 2025 profitability and confidence in VYKAT XR launch as rationale for buyback.

item 1.01 item 2.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

SOLENO THERAPEUTICS INC amended credit facility of $100.0 million with Oxford Finance LLC.

Instrument: credit facility
Principal: $100.0 million
Counterparty: Oxford Finance LLC
Event: amendment

Exact text from the filing

the remaining $100.0 million of loans under the Loan Agreement is uncommitted and may be made available only upon the mutual agreement of the Company and the Lenders

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

SOLENO THERAPEUTICS INC incurred senior notes of $100.0 million with Jefferies LLC.

Instrument: senior notes
Principal: $100.0 million
Counterparty: Jefferies LLC
Event: incurrence

Exact text from the filing

(the “ Company ”) entered into a confirmation and a supplemental confirmation (together, the “ ASR Agreement ”) of an accelerated share repurchase transaction with Jefferies LLC (the “ Dealer ”). Under the ASR Agreement, the Company shall repurchase an aggregate of $100.0 million of the Company’s common stock, $0.001 par value per share (the “ Common Stock ”).

View on SEC.gov

102 debt financings filed in the last 30 days. Browse all debt financings →

SOLENO THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-25-275674

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.